Replies to post #157193 on Biotech Values

[mcbio]

There's no question in my mind Sofo combined with IDX-719 couldn't provide the 90+% SVR rates that we are seeing in other genotypes.

As it pertains to IDX-719, was listening to the IDIX presentation at Leerink just now and there was discussion about the upcoming combo trials of 719 plus simeprevir, the JNJ non-nuke, and ritonavir. It was noted just after the 10 minute mark that simeprevir plus the non-nuke plus ritonavir would all be combined into one capsule. I thought that was interesting from a competitive standpoint. Not sure if there are plans to combine 719 with all those other components into one capsule. (I assume not.)